PASG vs. ELUT, ATRA, CGTX, TIL, CVM, ENTX, PLX, LENZ, GRTS, and DTIL
Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Elutia (ELUT), Atara Biotherapeutics (ATRA), Cognition Therapeutics (CGTX), Instil Bio (TIL), CEL-SCI (CVM), Entera Bio (ENTX), Protalix BioTherapeutics (PLX), LENZ Therapeutics (LENZ), Gritstone bio (GRTS), and Precision BioSciences (DTIL). These companies are all part of the "biological products, except diagnostic" industry.
Elutia (NASDAQ:ELUT) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
Passage Bio has a net margin of 0.00% compared to Passage Bio's net margin of -164.45%. Passage Bio's return on equity of 0.00% beat Elutia's return on equity.
Elutia presently has a consensus target price of $5.00, suggesting a potential upside of 51.52%. Passage Bio has a consensus target price of $9.00, suggesting a potential upside of 656.30%. Given Elutia's higher probable upside, analysts plainly believe Passage Bio is more favorable than Elutia.
74.0% of Elutia shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 40.8% of Elutia shares are owned by company insiders. Comparatively, 4.3% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Elutia has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.
Passage Bio received 43 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 66.67% of users gave Passage Bio an outperform vote.
Elutia has higher revenue and earnings than Passage Bio. Elutia is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Elutia had 1 more articles in the media than Passage Bio. MarketBeat recorded 3 mentions for Elutia and 2 mentions for Passage Bio. Passage Bio's average media sentiment score of 1.88 beat Elutia's score of 0.96 indicating that Elutia is being referred to more favorably in the media.
Summary
Elutia and Passage Bio tied by winning 8 of the 16 factors compared between the two stocks.
Get Passage Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Passage Bio Competitors List
Related Companies and Tools
